


**Pheno™ Analysis is a Highly Accurate and Robust Variant Classification Algorithm with High Tolerance for Reported Clinical History Errors**

Karla R. Bowles, PhD, FACMG  
May 9, 2018  
Session 1: 08:15 – 09:45



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)



**Disclosures**

---

I am employed by Myriad Genetic Laboratories, Inc. and receive salary and stock as compensation.



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)



### Methods

#### Clinical Testing: Informed Consent


- **Single syndrome**
- **Pan-cancer panel testing of up to 28 genes:** *BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, ATM, CHEK2, PALB2, MUTYH, APC, PTEN, TP53, STK11, SMAD4, CDH1, BARD1, BRIP1, CDKN2A, CDK4, BMPR1A, RAD51C, RAD51D, POLD1, POLE, GREM1*

#### Clinical History: Test Requisition

- **Patient:** Gender, ancestry, cancer(s) and age(s) of diagnosis, and current age
- **Family members:** Affected relatives with cancer type(s) and age(s) of diagnosis


#### Cancers Assessed by Pheno

- **Assessed cancers are gene-specific**
- **BRCA1/BRCA2:** Female Breast, Breast + Ovarian, Breast *in situ*, DCIS, Ovarian, Multiple Breast, Male Breast, Female Pancreatic, Male Pancreatic, Prostate, Lobular




Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)


### Pheno Starts By Scoring the Clinical History of Each Proband Carrying the Variant of Interest



**Proband A**  
Self – Breast 38  
Mother – Ovarian 55  
Brother – Breast 55



**Proband B**  
Self – Breast 55  
Mother – Breast 60  
Mat. Aunt – Breast 80




**Proband C**  
Self – Breast 78  
Father – Prostate 82



More Severe


Severity of Cancer History

Less Severe



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)





**Pheno is Optimized for Each Gene Individually:  
PPV and NPV Greater than 99.5%**

High Risk	Gene		Classification	# Variants Tests	NPV (%)	PPV (%)
	BRCA1		Pathogenic	27,000	99.90	99.72
			Benign	52,000		
	BRCA2		Pathogenic	27,000	99.90	99.71
			Benign	52,000		
	MLH1		Pathogenic	27,000	99.92	99.79
			Benign	52,000		
	MSH2		Pathogenic	27,000	99.93	99.72
			Benign	52,000		
	MSH6		Pathogenic	27,000	99.90	99.86
			Benign	52,000		

myriad  
WHEN DECISIONS MATTER

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com

Pheno is Optimized and Re-Validated At Least Every Two Years to Verify that PPV and NPV Remain Greater than 99.5%

	Gene	Classification	# Variants Tests	NPV (%)	PPV (%)
Moderate Risk	ATM	Pathogenic	26,000	99.94	99.81
		Benign	51,000		
	CHEK2	Pathogenic	26,000	99.87	99.87
		Benign	51,000		
	PALB2	Pathogenic	26,000	99.97	N/A*
		Benign	6,000		
	BARD1	Pathogenic	26,000	99.85	N/A*
		Benign	6,000		

\* Pheno is not currently used for *BARD1* or *PALB2* upgrades to pathogenic or likely pathogenic



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com

Will Pheno Work if Personal and Family History Data Contains Errors?

**Fact:** Patient cancer histories are obtained from the test requisition form, and patients may not report family histories correctly.


**Concern:** If the data used to generate a Pheno score isn't perfect, how can we trust the Pheno classification?

**Response:** Pheno has multiple design features which minimize the effect of clinical history errors on accuracy.



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com


# Pheno Places the Highest Weight on the Most Accurate Clinical Information




Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



# Pheno Scores are Based on Multiple Patients, Reducing the Impact of Limited History Errors



Pheno Score Based on Reported Cancer Histories



Pheno Score Based on Actual Cancer Histories


Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



## Pheno Makes the Correct Classification When Family History is Under-reported

**Fact:** TRF data is used for variant-carrying probands and probands used as pathogenic and benign controls

**Result:** If multiple patients under-report their family history, Pheno will make the correct classification call. All variant-specific and control scores shift together towards benign, but remain relatively similar



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com

## Pheno Makes the Correct Classification When Family History is Under-reported

Family members (if present) were randomly deleted from a percentage of probands carrying the same variant and from control probands: *50,000 benign and 25,000 pathogenic variants were tested through 2-fold cross-validations*

		% Probands: Two 2nd Degree Relatives Deleted			% Probands: One 1st and Two 2nd Degree Relatives Deleted		
Gene	Metric	10%	50%	100%	10%	50%	100%
BRCA1	PPV (%)	99.74	99.80	99.80	99.59	99.72	99.70
	NPV (%)	99.90	99.89	99.90	99.90	99.88	99.90
BRCA2	PPV (%)	99.65	99.81	99.78	99.84	99.88	99.85
	NPV (%)	99.90	99.89	99.90	99.88	99.90	99.90




Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



## Pheno Makes the Correct Classification When Family History is Over-reported

**Fact:** TRF data is used for variant-carrying probands and probands used as pathogenic and benign controls

**Result:** If multiple patients over-report their family history, Pheno will make the correct classification call. All variant-specific and control scores shift together towards pathogenic, but remain relatively similar.



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)



## Pheno Makes the Correct Classification When Family History is Over-reported

Affected sisters and/or aunts were randomly added to a percentage of probands carrying the same variant and to control probands: 50,000 benign and 25,000 pathogenic variants were tested through 2-fold cross-validations

Gene	Metric	% Probands: Two Affected Aunts Added			% Probands: One Affected Sister and Two Affected Aunts Added		
		10%	50%	100%	10%	50%	100%
BRCA1	PPV (%)	99.68	99.60	99.74	99.67	99.82	99.83
	NPV (%)	99.88	99.88	99.88	99.89	99.86	99.89
BRCA2	PPV (%)	99.54	99.59	99.80	99.63	99.75	99.76
	NPV (%)	99.90	99.89	99.89	99.91	99.87	99.90

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. [www.myriad.com](http://www.myriad.com)




## Pheno Makes the Correct Classification When Mixed History Errors are Present

**Fact:** TRF data is used for variant-carrying probands and probands used as pathogenic and benign controls


**Result:** If some patients over-report and others under-report family history, variant-specific Pheno scores look more like “an average” of pathogenic and benign. Pathogenic and benign control curves “slide together.” Pheno calls are more difficult to make, but are still accurate.

**If Pheno Makes a Call, It Is Correct**



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com

## We Tested the Effects of Mixed Family History Reporting Errors on Pheno Accuracy



1. Randomly select a proband, and replace that proband and all relatives with a random proband
2. Replace 1<sup>st</sup> and 2<sup>nd</sup> degree relatives without replacing the proband
3. Replace 2<sup>nd</sup> degree relatives without replacing the proband and 1<sup>st</sup> degree relatives

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



## Pheno Makes the Correct Classification When Mixed History Errors are Reported

Relative histories were replaced for a percentage of random probands carrying the same variant and for control probands: 50,000 benign and 25,000 pathogenic variants were tested through 2-fold cross-validations

Gene	Metric	% Probands: All 2 <sup>nd</sup> Degree Relatives Replaced			% Probands: All 1 <sup>st</sup> and 2 <sup>nd</sup> Degree Relatives Replaced		
		10%	20%	50%	10%	20%	50%
BRCA1	PPV (%)	99.74	99.64	99.75	99.70	99.79	99.68
	NPV (%)	99.89	99.89	99.88	99.90	99.89	99.91
BRCA2	PPV (%)	99.55	99.74	99.92	99.76	99.73	99.74
	NPV (%)	99.89	99.90	99.89	99.90	99.89	99.89

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



## Pheno Makes the Correct Classification When Mixed History Errors are Reported

Proband and relative histories were replaced for a percentage of random probands carrying the same variant and for control probands: 50,000 benign and 25,000 pathogenic variants were tested through 2-fold cross-validations

Gene	Metric	% Probands: Proband, 1 <sup>st</sup> and 2 <sup>nd</sup> Degree Relative Histories Replaced		
		10%	20%	50%
BRCA1	PPV (%)	99.68	99.75	99.76
	NPV (%)	99.86	99.87	99.73
BRCA2	PPV (%)	99.81	99.70	Fail
	NPV (%)	99.90	99.89	Fail

Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com



# Pheno Analysis is A Highly Accurate Algorithm



## Rigorously Developed and Validated

- Optimized for each gene
- >99.5% PPV and NPV



## Accurate in the Presence of Personal and/or Family History Errors

- Case-control design
- Will not make a call if data contains too many errors
- When Pheno makes a call, it is accurate



## Critical for Variant Reclassification and Appropriate Patient Care

- 2016: 23,337 amended reports; ~55% from Pheno
- Patients and family members may receive appropriate medical management



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com

# Thank You!

<b>BRCA1, BRCA2</b>	<ul style="list-style-type: none"><li>• Pruss D, <i>et al.</i> Development and validation of a new algorithm for the reclassification of genetic variants identified in the <i>BRCA1</i> and <i>BRCA2</i> genes. <i>Breast Cancer Res Treat.</i> 2014 147(1):119-132.</li></ul>
<b>MLH1, MSH2, MSH6</b>	<ul style="list-style-type: none"><li>• Morris B, <i>et al.</i> Classification of genetics variants in genes associated with Lynch syndrome using a clinical history weighting algorithm. <i>BMC Genet.</i> 2016 17(1):99.</li></ul>
<b>BRCA1, BRCA2</b>	<ul style="list-style-type: none"><li>• Bowles KR, <i>et al.</i> A clinical history weighting algorithm accurately classifies <i>BRCA1</i> and <i>BRCA2</i> variants. Presented ASHG, 2013.</li></ul>
<b>MLH1, MSH2, MSH6</b>	<ul style="list-style-type: none"><li>• Bowles KR, <i>et al.</i> Development of a novel history weighting algorithm for the reclassification of genetic variants identified in genes associated with Lynch syndrome. Presented ACMG, 2015.</li></ul>
<b>BRCA1, BRCA2, MLH1, MSH2, MSH6, ATM, CHEK2, PALB2</b>	<ul style="list-style-type: none"><li>• Bowles KR, <i>et al.</i> Reclassification of uncertain variants identified in high and moderate cancer risk genes using history weighting analysis. Presented ACMG, 2016.</li></ul>
<b>BRCA1, BRCA2, ATM, CHEK2, PALB2</b>	<ul style="list-style-type: none"><li>• Bowles KR, <i>et al.</i> Enhancement of history weighting analysis to accurately classify variants in high and moderate risk cancer panel genes. International Symposium on HBOC, 2016.</li></ul>
<b>BARD1</b>	<ul style="list-style-type: none"><li>• Added summer 2017 – Data on file</li></ul>



Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com